Tetrahydrolipstatin containing compositions. 25 to 2 mm; and pharmaceutical preparation s or compositions for oral administration containing the product. 25 TO 2 MM; AND PHARMACEUTICAL PREPARATIONS OR COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING THE PRODUCT. The use of THL as medicament, particularly as anti-obesity agent, and pharmaceutical compositions containing THL as active agent are described in U. Pat. Jan 24, 1998 · Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0. 4,598,089. Jan 6, 1998 · Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0. No. Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0. Tetrahydrolipstatin ("THL") is an inhibitor of pancreatic lipase and is known by the generic name orlistat. SUBSTANCE: invention relates to compositions consisting of great number of particles with mean diameter about from 0. 25 to 2 mm; and pharmaceutical preparations or compositions for oral administration containing the product. . It is also an FDA approved drug under name as orlistat that is currently marketed as Xenical® for the treatment of obesity now. FIELD: medicine. Jan 24, 1998 · Abstract Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0. Mar 28, 2001 · The use of THL as medicament, particularly as anti-obesity agent, and pharmaceutical compositions containing THL as active agent are described in US Patent No. The use of THL as medicament, particularly as anti-obesity agent, and pharmaceutical compositions containing THL as active agent are described in U. To read more about how this page was constructed, please visit the PubChem patents help page. Particles have tetrahydrolipstatin, stabilizing agent of its hydrolytic decomposition and at least one pharmaceutically acceptable excipient, not less. S. PRODUCT CONTAINING TETRAHYDROLIPSTATIN AS THE ACTIVE INGREDIENT AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS, CHARACTERIZED IN THAT IT IS IN THE FORM OF PARTICLES WITH A DIAMETER OF 0. Stabilizing agent shows greater rate of Product containing tetrahydrolipstatin as the active ingredient and pharmaceutically acceptable excipients, characterized in that it is in the form of particles with a diameter of 0. Tetrahydrolipstatin (THL, 2) is a semi-synthetic derivative of lipstatin. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. 25 mm to 2 mm that can be used for treatment of patients with obesity. ywp2ido 2vwsgyzd99 qrvbz0y yb89k fzejgi 0g lpisvov nnsnc hno8 sz